DeepMed Research

Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Clinical Trials

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2005-09-28

Last Posted Date: 2013-02-13

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 221

Registration Number: NCT00228397

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

Completed

Conditions: Squamous Cell Carcinoma

First Posted Date: 2005-09-19

Last Posted Date: 2007-12-27

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 20

Registration Number: NCT00195299

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Temsirolimus (CCI-779)
Drug: Investigator's choice

First Posted Date: 2005-07-07

Last Posted Date: 2015-03-30

Lead Sponsor: Pfizer

Target Recruit Count: 169

Registration Number: NCT00117598

Locations: 🇬🇧
Pfizer Investigational Site, Sutton, Surrey, United Kingdom

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 1

Completed

Conditions: Stage IV Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer

Interventions: Drug: CCI-779
Drug: Bevacizumab

First Posted Date: 2005-06-03

Last Posted Date: 2022-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00112840

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Diffuse Astrocytoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Pilocytic Astrocytoma
Adult Mixed Glioma
Adult Pineal Gland Astrocytoma
Adult Subependymal Giant Cell Astrocytoma

Interventions: Drug: erlotinib
Drug: temsirolimus
Other: pharmacological study
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2005-06-03

Last Posted Date: 2015-06-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT00112736

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 5 locations

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Melanoma
Recurrent Renal Cell Cancer
Stage IV Melanoma
Stage IV Renal Cell Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bryostatin 1
Drug: temsirolimus

First Posted Date: 2005-06-03

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00112476

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma

Interventions: Biological: rituximab
Drug: temsirolimus

First Posted Date: 2005-05-04

Last Posted Date: 2014-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 71

Registration Number: NCT00109967

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸
Graham Hospital Association, Canton, Illinois, United States

and more 190 locations

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Phase 1

Completed

Conditions: Adenocarcinoma
Neoplasms

Interventions: Drug: Torisel

First Posted Date: 2005-03-23

Last Posted Date: 2013-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT00106353

Locations: 🇷🇺
Pfizer Investigational Site, Saint Petersburg, Russian Federation

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesylate
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2005-01-10

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00101088

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pelitinib
Drug: temsirolimus

First Posted Date: 2004-12-08

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00098501

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy